Targeted Oncology1h
Study Launches of QXL138AM in Multiple Myeloma and Solid Tumors
Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...
Targeted Oncology4h
FDA Approves IND for AS1986NS, a New Approach in Prostate Cancer Research
The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.
Targeted Oncology3h
FDA Approves Nilotinib With No Mealtime Restrictions in Ph-Positive CML
The FDA has approved a re-engineered formulation of nilotinib with no mealtime restrictions for adult patients with newly ...
Targeted Oncology19h
Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease
In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their ...
Targeted Oncology23h
The Lasting Impact of the CROSS Trial on GEJ Cancer Care
Yanghee Woo, MD, provides an overview of the CROSS trial which focused on treating patients with gastroesophageal junction ...
Targeted Oncology22h
FDA Approval Sought for Dato-DXd in EGFR-Mutated NSCLC
A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...
Targeted Oncology1d
Campbell Surveys Participants on Favorable-Risk Frontline Approach in RCC
During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...
Targeted Oncology1d
SELECT-MDS-1 Trial of Tamibarotene Misses Primary End Point in MDS
The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for ...
Targeted Oncology1d
Balancing Clinical Data and Real-World Insights in CML Treatment
In an interview with Targeted Oncology, Michael Mauro, MD, delved into the rapidly advancing field of chronic myeloid ...
Targeted Oncology1d
New Therapies Expand Options in Recurrent Small Cell Lung Cancer
Chavez, MD, discusses the current approach to managing recurrent small cell lung cancer especially in patients who have ...
Targeted Oncology2d
Fellow's Perspective: Patient Case of Newly Diagnosed Multiple Myeloma
In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and ...
Targeted Oncology3d
Nivolumab-Chemotherapy Combo Boosts PFS in cHL, Poised for Standard Use
The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, ...